WSJ News Exclusive | For Covid-19 Vaccine, J&J Plans 60,000-Subject Pivotal Trial

Johnson & Johnson plans to start a late-stage trial for the company’s Covid-19 vaccine in late September, and aims to enroll 60,000 subjects.

Read the full article here

Related Articles